

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

ALEXION PHARMACEUTICALS INC
Form 8-K
August 05, 2003

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2003

ALEXION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

0-27756
(Commission File Number)

13-3648318
(IRS Employer Identification No.)

352 Knotter Drive
Cheshire, CT 06410
(Address of Principal Executive Offices)

Registrant's telephone number, including area code (203) 272-2596

None
(Former Name or Former Address, if Changed Since Last Report.)

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(a) Financial Statements.

None.

(b) Pro Forma Financial Information.

None.

(c) Exhibits

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

99.1. Press Release of Alexion Pharmaceuticals, Inc. (the "Company") issued on August 4, 2003 announcing preliminary results of its Phase III PRIMO-CABG Trial.

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.

On August 4, 2003, the Company announced preliminary results of its Phase III PRIMO-CABG Trial. A copy of the press release issued by the Company relating thereto is furnished herewith as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Alexion Pharmaceuticals, Inc.

/s/ Leonard Bell

By: Leonard Bell

Title: Chief Executive Officer

Dated: August 4, 2003